Alterity Therapeutics' 1-for-50 Reverse Stock Split Becomes Effective
ATHE sits 51% above its 52-week low of $2.66.
Summary
Alterity Therapeutics has completed its 1-for-50 reverse stock split, consolidating its share capital and adjusting the per-share price accordingly.
Key Events · Corporate Governance and Compliance · ATHE
-
Reverse Stock Split Effective
The company's 1-for-50 reverse stock split, approved by shareholders on May 29, 2026, is now effective.
-
Temporary Trading Code
Shares will trade under the temporary ASX code "ATHDA" until June 11, 2026, with normal trading resuming on June 12 under "ATH".
-
Share Capital Consolidation
Shareholder holdings have been reduced by a 1-for-50 ratio, with fractional entitlements rounded up.
Analysis · ATHE · Life Sciences
This filing confirms the execution of the 1-for-50 reverse stock split, previously approved by shareholders on May 29, 2026. This action significantly reduces the number of outstanding shares and proportionally increases the per-share price, aiming to meet exchange listing requirements and potentially attract broader institutional investment. While a reverse split doesn't change the company's overall market capitalization, it can impact investor perception and liquidity.
At the time of this filing, ATHE was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.2M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.